Neuren Pharmaceuticals (ASX:NEU) reported Friday 2024 earnings of AU$1.0861 per diluted share, down from AU$1.2012 a year earlier.
Analysts polled by Visible Alpha expected a diluted EPS of AU$0.95.
Revenue from ordinary activities for the year ended Dec. 31, 2024, was AU$227.8 million, down from AU$240.1 million a year earlier. Analysts surveyed by Visible Alpha expected AU$194.8 million.
Neuren anticipates earning royalties of AU$62 million to AU$67 million, assuming its global partner for trofinetide, Nasdaq-listed Acadia, meets its full-year net sales guidance of $380 million to $405 million for 2025, per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。